Weekly News Wrap-Up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca’s Selumetinib, that failed last year as a treatment for a rare cancer of the eye, has been
awarded special orphan status in the United States for a type of thyroid cancer. (foxnews.com)
Elekta announced that Medica a Health Group, o e of Turkey’s largest private health care networks,
purchases equipment and software for more than €10 million. (finance.yahoo.com)
Genmab reported Q1 revenues of $26.03 million, meaning an increase of 59% versus the same
quarter last year. Q1 operating profit shrank by 90% to $2.4 million. (reuters.com)
Roche is in talks with South Africa to reduce the price of its breast cancer drug Herceptin, which was
unaffordable to most women, according to the country’s health minister. (reuters.com)
Stada reported first-quarter net income of €29.6 illio , 40% higher than last year. Its adjusted net
income was €40.1 million compared to €37.9 million the year before. (nasdaq.com)
William Demant maintains its 2016 guidance after a successful Q1 with growth in all business
activities. EBIT is expected to reach $306-352 million in 2016. (reuters.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 11
2016-05-14
Allergan AstraZeneca Biogen Bristol-Myers Squibb Chugai CSL Elekta
Genmab Pfizer Roche Santen Stada Varian William Demant
SPOTLIGHT
COMPANY NEWS
Allergan said it plans to buy back as much as $10 billion in stock after completing the $40 billion sale
of its generics business to Teva Pharmaceutical Industries. (bloomberg.com)
Biogen and Swedish Orphan announced that the European Commission has approved Alprolix, their
extended half-life therapy, for the treatment of haemophilia B. (streetinsider.com)
Bristol-Myers Squibb and AbbVie announced European Commission approval of Empliciti
(elotuzumab) for the treatment of multiple myeloma in adult patients. (reuters.com)
Pfizer and its immuno-oncology partner Merck KGaA will combine three experimental cancer drugs
in humans in an early-stage study. (fiercebiotech.com)
Varian announced the release of new computer aided engineering (CAE) software for simplifying the
process of designing shielding and radiological protection systems. (prnewswire.com)
Chugai has revealed that a lawsuit was filed against the company at the Tokyo District Court by US
biotechnology firm Baxalta over hemophilia A drug patent. (thepharmaletter.com)
CSL’s Idelvio got European Commission approval for the treatment and prophylaxis of bleeding in
patients with hemophilia B. It also received 7 years of exclusivity in USA. (thepharmaletter.com)
Santen announced revenues of $1.79 billion for fiscal year 2015 ended March 31, meaning +20.7%
compared to last year (in home currency). (globenewswire.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
98%
100%
102%
104%
2016-05-09 2016-05-10 2016-05-11 2016-05-12 2016-05-13
Europe North America Asia/Pacific
Regional Comparison
Focus on Europe
Looking at this week’s sto k perfor a e of the world’s iggest listed health are o pa ies, a gai
of +1.4% has been achieved whereas the one year change shows a loss of -8.0%. The strongest region
was Europe with an increase of +2.8%, followed by Asia/Pacific with +1.2% and North America with
+0.9%. In contrast to Asia/Pacific, the first two regions suffered from a loss on a yearly basis.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 11
2016-05-14
BB Biotech Coloplast Genmab Indivior Ipsen
Meda Qiagen Recordati Stada William Demant
SPOTLIGHT
FINANCIAL MARKET NEWS
The lead of this week’s perfor a e ra ki g fro Europea health care companies is taken by
Indivior, gaining +7.4% though its one year change amounts to a loss of -28.9%. Second place goes to
Genmab, reaching +6.2% on a weekly basis while its one year performance is +90.0%.
This week’s lowest perfor a e of Europea health are o pa ies o es fro William Demant,
suffering from a decline of -2.0% while its one year gai a ou ts to + .8%. Followi g suit, Qiage ’s
stocks dropped -1.8% this week, while it lost -13.0% on a yearly basis.
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
709.13 +2.77% -12.81% 713.52 694.14 876.66 654.95
STOXX® North America 600
Health Care
801.38 +0.89% -8.16% 813.91 793.44 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
438.42 +1.16% +13.54% 439.69 432.39 454.36 349.32
STOXX® Global 1800
Health Care
707.56 +1.42% -7.96% 714.60 698.03 842.76 647.94
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
William Demant 88.59 -2.00% +21.79% 93.13 88.08 93.86 66.45
Qiagen 21.39 -1.79% -12.99% 22.04 21.19 28.53 20.10
BB Biotech 42.70 -1.76% -19.39% 45.60 42.70 62.40 35.50
Coloplast 65.97 -1.44% -4.34% 66.81 65.71 78.58 55.69
Meda 146.75 -1.42% +14.05% 148.68 146.40 153.40 83.90
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Indivior 162.40 +7.40% -28.86% 162.40 152.00 271.40 126.60
Genmab 135.66 +6.15% +90.02% 135.66 128.19 135.39 67.98
Recordati 24.19 +5.91% +30.15% 24.36 22.86 24.44 18.13
Ipsen 54.27 +5.47% +6.14% 54.54 52.14 64.13 45.73
Stada 41.55 +5.26% +24.35% 41.75 39.17 41.61 28.07